Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
164.07M | 1.19M | 0.00 | 0.00 | 0.00 | Gross Profit |
40.08M | -9.57M | -21.14M | -13.98M | -8.71M | EBIT |
-395.28M | -460.56M | -398.88M | -342.70M | -261.94M | EBITDA |
-395.28M | -427.43M | -374.76M | -328.27M | -250.87M | Net Income Common Stockholders |
-372.18M | -444.04M | -389.92M | -327.82M | -257.23M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
323.78M | 279.87M | 471.85M | 596.00M | 629.44M | Total Assets |
910.43M | 780.35M | 663.98M | 777.33M | 768.46M | Total Debt |
57.26M | 75.86M | 84.45M | 71.53M | 51.66M | Net Debt |
-58.43M | -39.03M | -147.28M | -6.70M | -15.67M | Total Liabilities |
200.02M | 195.74M | 164.34M | 155.67M | 111.96M | Stockholders Equity |
710.40M | 584.61M | 499.64M | 621.66M | 656.50M |
Cash Flow | Free Cash Flow | |||
-364.05M | -384.11M | -313.18M | -265.51M | -251.93M | Operating Cash Flow |
-352.98M | -361.82M | -292.76M | -227.94M | -205.13M | Investing Cash Flow |
-96.41M | -155.24M | 256.45M | 132.00K | -317.85M | Financing Cash Flow |
390.66M | 462.96M | 190.15M | 239.27M | 576.42M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
63 Neutral | $1.24B | ― | -12.27% | ― | 3.08% | -247.82% | |
57 Neutral | $1.00B | ― | -36.26% | ― | 127.33% | 21.31% | |
53 Neutral | $5.24B | 3.07 | -43.58% | 2.80% | 16.87% | -0.11% | |
51 Neutral | $1.05B | ― | -49.41% | ― | 4.86% | 10.13% | |
48 Neutral | $800.24M | ― | -93.70% | ― | ― | -25.83% | |
42 Neutral | $1.12B | ― | -69.30% | ― | ― | -68.13% | |
39 Underperform | $611.10M | ― | -51.85% | ― | 11070.12% | 32.07% |
Iovance Biotherapeutics is set to relocate its headquarters within the same building in San Carlos, California, opting for a smaller space to reduce costs amid an increase in remote work. The new lease significantly lowers their monthly rent from $279,540.80 to an initial $99,549.53, reflecting the company’s strategic cost-cutting measures. This move follows the termination of their previous lease for a larger space, highlighting their focus on financial efficiency.